Experts have warned that those who have underlying medical conditions or who are immunocompromised are especially vulnerable to the impact of the coronavirus. This warning has raised questions on how to manage patients using immunomodulatory therapies for their dermatologic conditions. Accordingly, the American Academy of Dermatology has released interim recommendations on the use of biologic therapy during the current COVID-19 outbreak.

 

The FDA has approved a supplemental Biologics License Application for Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Following phase 3 of a pediatric study, half of the patients treated with Taltz achieved completely clear skin after only 12 weeks of treatment.

 

The American Academy of Dermatology and the National Psoriasis Foundation have released the first joint guidelines of care for the treatment of pediatric psoriasis patients. The guidelines offer an extensive review of best practices, and comorbidities--including the psychosocial impact which the guideline suggests must especially be given more attention to among pediatric psoriasis patients.

David M. Pariser, M.D. addresses the unpredictable nature of combining psoriasis topicals.

Dr. Leon H. Kircik, MD, discusses various emerging pharmaceutical treatment options for acne and rosacea.